AZNAstraZenecaRunning, no new patients
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Breast Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 1,837 (final count)
- Started
- Apr 22, 2014
- Main results expected
- Mar 27, 2020
- Fully finished
- May 28, 2029
- Results posted
- Dec 8, 2021
What counts as success
The trial's main goal(s), called the “primary outcome.”
Invasive Disease Free Survival (IDFS)
Measured over: From date of randomisation to data cut off: 27 March 2020 (approximately 5 years 11 months)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT02032823 · record last updated 2026-07-14 · checked 2026-11-09 15:47 UTC